Landscape of somatic alterations in large-scale solid tumors from an Asian population

[1]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[2]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[3]  F. Meric-Bernstam,et al.  Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients , 2020, JCO precision oncology.

[4]  Wei Zhu,et al.  The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China , 2020, Experimental Hematology & Oncology.

[5]  Jacob Josiah Santiago Alvarez,et al.  Genomic landscape of lung adenocarcinoma in East Asians , 2020, Nature Genetics.

[6]  Yuwei Cheng,et al.  An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. , 2019, The oncologist.

[7]  M. Provencio,et al.  Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. , 2019, European journal of cancer.

[8]  Y. Jiang,et al.  Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  E. Jaffee,et al.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. , 2019, JCI insight.

[10]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[11]  V. Miller,et al.  Approach to evaluating tumor mutational burden in routine clinical practice. , 2018, Translational lung cancer research.

[12]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[13]  J. Sicklick,et al.  Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors , 2018, JAMA oncology.

[14]  Elaine R. Mardis,et al.  The emerging clinical relevance of genomics in cancer medicine , 2018, Nature Reviews Clinical Oncology.

[15]  Mark D. M. Leiserson,et al.  Precision Oncology: The Road Ahead. , 2017, Trends in molecular medicine.

[16]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[17]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[18]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[20]  M. Villalona-Calero,et al.  Race and Ethnicity in Cancer Therapy: What Have We Learned? , 2014, Clinical pharmacology and therapeutics.

[21]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[22]  M. Ladanyi,et al.  Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  I. Iakovidis,et al.  The road ahead. , 2004, Studies in health technology and informatics.